Finley Financial LLC Purchases New Position in iShares Biotechnology ETF (NASDAQ:IBB)

Finley Financial LLC purchased a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 675 shares of the financial services provider’s stock, valued at approximately $90,000.

Several other institutional investors and hedge funds also recently made changes to their positions in IBB. Darwin Wealth Management LLC bought a new stake in shares of iShares Biotechnology ETF during the 3rd quarter valued at $29,000. Highline Wealth Partners LLC purchased a new position in shares of iShares Biotechnology ETF during the 3rd quarter valued at $30,000. Ashton Thomas Securities LLC purchased a new position in shares of iShares Biotechnology ETF during the 3rd quarter valued at $36,000. Modus Advisors LLC purchased a new position in shares of iShares Biotechnology ETF during the 4th quarter valued at $41,000. Finally, Voisard Asset Management Group Inc. purchased a new position in shares of iShares Biotechnology ETF during the 3rd quarter valued at $59,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Up 2.6 %

Shares of IBB stock opened at $136.10 on Wednesday. iShares Biotechnology ETF has a 52 week low of $123.60 and a 52 week high of $150.57. The company’s fifty day simple moving average is $136.15 and its two-hundred day simple moving average is $141.84.

iShares Biotechnology ETF Cuts Dividend

The business also recently declared a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.